Medifil® II Collagen Particles, Skin Temp® II Collagen Sheets, and Collatek® Gel for Venous Leg Ulcers (VLUs)

Venous leg ulcers (VLUs) are chronic wounds caused by impaired venous circulation that often require advanced, multimodal treatment strategies. Effective management focuses on improving venous return, protecting skin integrity, and supporting tissue regeneration. Collagen-based wound care products, when used alongside compression therapy, play a critical role in optimizing healing outcomes for patients with VLUs.

Understanding Venous Leg Ulcers

Venous leg ulcers occur when blood leaks from veins into surrounding skin tissue, leading to skin breakdown and ulcer formation. These ulcers develop when venous blood does not return efficiently to the heart. Both men and women are affected, particularly individuals with prior leg injuries, varicose veins, venous thrombosis, multiple pregnancies, obesity, or occupations involving prolonged standing or sitting.

Managing Venous Insufficiency to Support Healing

Compression therapy and leg elevation are foundational components of venous insufficiency management. Properly fitted compression stockings assist venous return and should be replaced every six months to maintain therapeutic effectiveness. Patients are advised to avoid leg crossing, shift weight when standing for extended periods, and avoid restrictive clothing that impairs circulation.

Lifestyle modifications, daily skin hydration, and consistent compression therapy help reduce recurrence and support long-term wound closure.

Role of Collagen Dressings in Venous Leg Ulcer Care

Venous leg ulcers are prone to recurrence and chronic inflammation. Collagen dressings used in conjunction with compression bandaging have demonstrated clinical benefits in difficult-to-heal VLUs, including improved tissue regeneration and enhanced patient quality of life.

Collagen advanced wound care dressings help regulate excessive protease activity while promoting tissue growth, angiogenesis, collagen deposition, autolytic debridement, and wound re-epithelialization.

Collagen Dressing Technology and Clinical Performance

Kollagen™ Technology, developed by Human BioSciences, preserves the native triple helix structure of non-hydrolyzed type I bovine collagen. Maintaining this structure ensures superior molecular stability, scaffold integrity, and bioactivity throughout all phases of wound healing.

Native collagen binds and inactivates elevated matrix metalloproteinases (MMPs), a hallmark of chronic wounds, thereby restoring balance within the wound microenvironment and facilitating healing progression.

Product Features and Functional Benefits

Medifil® II Collagen Particles, SkinTemp® II Collagen Sheets, and Collatek® Collagen Gel offer the following properties:

• Compatibility with topical agents and secondary dressings
• Absorptive and hemostatic characteristics
• Promotion of angiogenesis and granulation tissue formation
• Reduction of elevated MMP activity
• Accelerated healing timelines
• Cuttable sheets for surface wounds
• Particles suitable for undermining and tunneling
• Available in multiple sizes
• Extended shelf life

Clinical Indications and Application Guidance

Indications include:

• Acute and chronic wounds
• Partial- and full-thickness wounds
• Non-infected and infected wounds
• Light to moderately exudating wounds

Do not use:

• On third-degree burns
• In patients with bovine sensitivities

Application is straightforward and compatible with other topical therapies. Products should be gently placed into wound beds, including undermining and tunneling areas when present. Dressing change frequency depends on wound assessment, drainage levels, and physician direction, with wear times ranging from one to seven days. Secondary dressings are required for most applications.

The objective is evidence-based advanced wound care aligned with established clinical standards to achieve optimal healing outcomes.

References

Brenner M, Albert P, Raminfard A. Collagen Treatment in the Diabetic Foot. The Diabetic Foot. 2019 November/December. Podiatry Management. https://podiatrym.com/pdf/2019/11/Brenner1119Web.pdf last accessed September 17, 2020.

Gibson DJ, Schultz GS. Molecular Wound Assessments: Matrix Metalloproteinases. Adv Wound Care (New Rochelle). 2013;2(1):18-23. doi: 10.1089/wound.2011.0359

Chattopadhyay S, Raines RT. Review collagen-based biomaterials for wound healing. Biopolymers. 2014;101(8):821-833. doi: 10.1002/bip.22486

Xenogeneic extracellular matrix as a scaffold for tissue reconstruction. Badylak SF Transpl Immunol. 2004 Apr; 12(3-4):367-77. Westgate, S., Cutting, K. F., Deluca, G., & Assad, K. (n.d.).

Collagen dressings Made Easy (page 1 of 3) › Made Easy › Wounds UK. Retrieved September 17,2020 from http://www.wounds-uk.com/made-easy/collagen-dressings-made-easy.
Ayello E.A., Baranoski S., Kerstein M.D., Cuddigan J. Wound treatment options. In: Baranoski S., Ayello E.A., editors. Wound Care Essentials: Practice Principles. Lippincott Williams & Wilkins; Philadelphia, PA: 2003. p. 138

León-López A, Morales-Peñaloza A, Martínez-Juárez VM, Vargas-Torres A, Zeugolis DI, Aguirre-Álvarez G. Hydrolyzed Collagen-Sources and Applications. Molecules. 2019;24(22):4031. Published 2019 Nov 7. doi:10.3390/molecules24224031

Fleck CA, Simman R. Modern collagen wound dressings: function and purpose. J Am Col Certif Wound Spec. 2011;2(3):50-54. Published 2011 Aug 1. doi: 10.1016/j.jcws.2010.12.003

Human BioSciences, Inc. blog offers education and tips; however,the information provided by this website or company is not a substitute for medical treatment or advice.

FAQ